7RLX
Antibody 2F2 in complex with P. vivax CSP peptide GDRADGQPAGDRAAGQPA
Summary for 7RLX
| Entry DOI | 10.2210/pdb7rlx/pdb |
| Descriptor | 2F2 Fab light chain, 2F2 Fab heavy chain, peptide from Circumsporozoite protein variant VK210, ... (4 entities in total) |
| Functional Keywords | antibody, malaria, plasmodium vivax, circumsporozoite protein, antimicrobial protein |
| Biological source | Mus musculus (mouse) More |
| Total number of polymer chains | 3 |
| Total formula weight | 50042.70 |
| Authors | Kucharska, I.,Julien, J.P. (deposition date: 2021-07-26, release date: 2022-01-26, Last modification date: 2023-10-18) |
| Primary citation | Kucharska, I.,Hossain, L.,Ivanochko, D.,Yang, Q.,Rubinstein, J.L.,Pomes, R.,Julien, J.P. Structural basis of Plasmodium vivax inhibition by antibodies binding to the circumsporozoite protein repeats. Elife, 11:-, 2022 Cited by PubMed Abstract: Malaria is a global health burden, with (Pf) and (Pv) responsible for the majority of infections worldwide. Circumsporozoite protein (CSP) is the most abundant protein on the surface of sporozoites, and antibodies targeting the central repeat region of CSP can prevent parasite infection. Although much has been uncovered about the molecular basis of antibody recognition of the PfCSP repeats, data remains scarce for PvCSP. Here, we performed molecular dynamics simulations for peptides comprising the PvCSP repeats from strains VK210 and VK247 to reveal how the PvCSP central repeats are highly disordered, with minor propensities to adopt turn conformations. Next, we solved eight crystal structures to unveil the interactions of two inhibitory monoclonal antibodies (mAbs), 2F2 and 2E10.E9, with PvCSP repeats. Both antibodies can accommodate subtle sequence variances in the repeat motifs and recognize largely coiled peptide conformations that also contain isolated turns. Our structural studies uncover various degrees of Fab-Fab homotypic interactions upon recognition of the PvCSP central repeats by these two inhibitory mAbs, similar to potent mAbs against PfCSP. These findings augment our understanding of host interactions and contribute molecular details of Pv inhibition by mAbs to unlock structure-based engineering of PvCSP-based vaccines. PubMed: 35023832DOI: 10.7554/eLife.72908 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.97 Å) |
Structure validation
Download full validation report
